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Objectives: To assess whether mitochondrial dysfunction in skeletal muscle characterizes antiretroviral therapy
(ART)-associated lipoatrophy (LA).
Methods: A cross-sectional study comparing HIV-infected, antiretroviral-treated patients with LA (n¼5; LA+)
and without LA (n¼5; non-LA) was conducted. Positron emission tomography was used to measure blood
flow, oxygen extraction and oxygen consumption in quadriceps femoris muscle during rest and aerobic
exercise. Mitochondrial DNA (mtDNA) was quantified by PCR. Body composition was measured by dual-
energy X-ray absorptiometry and magnetic resonance imaging. All data are given as means+SEM.
Results: Compared with the non-LA group, the LA+ group had significantly less limb fat and more intra-
abdominal fat, but similar leg muscle mass. The LA+ group versus the non-LA group had reduced mtDNA
content per nucleus in adipose tissue (173+38 versus 328+62; P¼0.067), but not in skeletal muscle
(2606+375 versus 2842+309; P¼0.64). Perfusion in resting muscle (34+7 versus 28+6 mL/kg/min in the
LA+ group versus the non-LA group; P¼0.5), and the mean absolute (277+30 versus 274+43 mL/kg/min,
respectively; P¼0.95) and relative (10.6+2.5- versus 11.9+1.5-fold change, respectively; P¼0.67) increases
in perfusion during exercise were similar between the groups. Oxygen consumption at rest (2.2+0.7 versus
2.1+0.3 mL/kg/min in the LA+ group versus the non-LA group; P¼0.9), and the mean absolute (14.6+1.7
versus 24.3+8.8 mL/kg/min, respectively; P¼0.3) and relative (10.3+2.8- versus 11.7+2.4-fold change,
respectively; P¼0.73) exercise-induced increases in oxygen consumption were similar between the groups.
The oxygen extraction fraction was comparable between the groups, both at rest and during exercise.
Plasma lactate concentrations remained unchanged in both groups during exercise.
Conclusions: HIV-infected patients with ART-associated LA have similar mtDNA content in skeletal muscle and
comparable skeletal muscle aerobic exercise metabolism to antiretroviral-treated non-lipoatrophic patients.
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Introduction
The prognosis of HIV-infected patients treated with combination
antiretroviral therapy (ART) appears to approach that of the
general population.1 However, ART is also associated with long-
term metabolic side effects, such as lipodystrophy, i.e. loss of sub-
cutaneous fat [lipoatrophy (LA)] with or without accumulation of
intra-abdominal fat, dyslipidaemia and insulin resistance.2
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Drug-induced mitochondrial toxicity appears to be a key
feature in the pathophysiology of ART-associated LA.3 Nucleoside
analogue reverse transcriptase inhibitors (NRTIs) inhibit mito-
chondrial DNA polymerase g, leading to the depletion of mito-
chondrial DNA (mtDNA).4 In keeping with these in vitro data,
several studies have shown mtDNA to be reduced in lipoatrophic
subcutaneous adipose tissue of antiretroviral-treated patients.5,6
This may impair mitochondrial function and, for example, the
translation of mtDNA-encoded components of the respiratory
chain complex may decrease.
At present it is unknown how uniformly different human
tissues are affected by the NRTI-induced mitochondrial toxicity.
Data regarding the mtDNA content of peripheral blood mono-
nuclear cells are conflicting, showing both unchanged7,8 and
decreased9 mtDNA content in patients with ART-associated lipo-
dystrophy. The mtDNA content has even been shown to be
increased in CD4+ lymphocytes in patients with ART-associated
lipodystrophy.10 Data are scarce and inconsistent on whether
NRTI-induced LA (i.e. mitochondrial toxicity in adipose tissue) is
associated with mitochondrial toxicity also in skeletal muscle, a
tissue rich in mitochondria.
The NRTI zidovudine was widely used as single drug therapy
in the early 1990s, before current combination therapies were
available. Although zidovudine-associated myopathy is a
known complication of high-dose zidovudine monotherapy,11
these patients have not been reported to have lipodystrophy.
The latter was first reported as a complication of ART in
1997–812,13 and has been associated with the use of combi-
nation therapies, possibly implying a different pathophysiology.
A recent animal model has shown that zidovudine, but not
zalcitabine, induces mitochondrial myopathy with mtDNA
depletion.14 In addition, a recent microarray study demonstrated
significant dose-related effects of zidovudine on the expression
of genes associated with apoptosis, fatty acid metabolism,
mitochondrial genome maintenance and various mitochondrial
membrane transporters in the skeletal muscle of infant mice.15
Interestingly, although the number of patients receiving zidovu-
dine as part of ART dramatically increased during the late 1990s
and although up to 50% of patients on ART may develop lipody-
strophy,16,17 the prevalence of skeletal muscle complications
has not increased similarly. Conversely, data from France
suggest that there has been a marked decrease in the number
of muscle biopsies performed in HIV-infected individuals in
neuromuscular centres since 1998.18
The production of adenosine triphosphate (ATP) in skeletal
muscle is dependent on mitochondrial function. Therefore,
significant mitochondrial dysfunction, potentially caused by
ART, should impair the aerobic exercise capacity of skeletal
muscle. Skeletal muscle could possibly compensate this
impairment by increasing blood flow and/or oxygen consump-
tion. Positron emission tomography (PET) is the most
advanced scintigraphic imaging technique in humans that
allows non-invasive studies of metabolism and perfusion
in vivo.19
In the current study, we aimed to evaluate whether skeletal
muscle is affected in ART-associated LA by measuring the
mtDNA content in skeletal muscle, and by using the unique fea-
tures of PET to directly measure blood flow and oxygen con-
sumption in skeletal muscle during rest and aerobic exercise in
patients with and without ART-associated LA.
Materials and methods
Study design
This is a cross-sectional study comparing HIV-infected, antiretroviral-
treated patients with LA (LA+ group) and HIV-infected, antiretroviral-
treated patients without LA (non-LA group).
The purpose, nature and potential risks of the study were explained to
the study subjects before their informed consent was obtained. The study
protocol was approved by the ethics committees of Helsinki (clinical
studies other than PET) and Turku (PET) University Central Hospitals.
Subjects
The patients were recruited from the HIV outpatient clinic of Helsinki Uni-
versity Central Hospital. Inclusion criteria included: male gender; age
.18 years; clinically stable HIV infection; and ≥2 year duration of combi-
nation ART prior to study entry. In addition, patients in the LA+ group had
self-reported symptoms of loss of subcutaneous fat with or without
increased abdominal girth. Patients in the non-LA group had used ART
without developing LA. The presence or absence of symptoms of lipo-
dystrophy was confirmed by the study physician (J. S.) prior to entry
into the study.
Body composition
Limb fat, truncal fat, total body fat and lean body mass were measured
using dual-energy X-ray absorptiometry (DEXA; Lunar Prodigy, Madison,
WI, USA). Intra-abdominal fat and subcutaneous fat of the abdomen
were quantified by analysing a total of 16 T1-weighted trans-axial
magnetic resonance imaging (MRI) scans, reaching from 8 cm above to
8 cm below the fourth and fifth lumbar interspace (field of view
375×500 mm2, slice thickness 10 mm, breath-hold repetition time
138.9 ms, echo time 4.1 ms), as previously described.20 MRI scans were
analysed by a single investigator using image analysis software (Alice
3.0, Parexel, Waltham, MA, USA). Investigators analysing body compo-
sition data were blinded to patient disposition in the LA+ or non-LA
groups.
PET
After measuring maximal isometric knee-extension contraction force
(MVC), PET scanning for the measurement of blood flow and oxygen con-
sumption in skeletal muscle was performed. The subjects were instructed
to avoid exercise during the last 3 days before the measurement. More-
over, they were asked to avoid caffeinated beverages for 24 h and to fast
overnight for 10 h before the experiment.
One hour before the PET measurement, two catheters were inserted,
one into an antecubital vein for infusion of saline and injection of tracer,
and the other into the opposite radial artery for blood sampling. There-
after, subjects were attached to the PET scanner, as described before.21
While adjusting the dynamometer, the subject performed a 5 min fam-
iliarization and warm-up with the dynamometer. After the transmission
scan, two 12 min dynamic knee-extension exercise periods with a
10 min recovery between the sets were performed with the right leg in
a continuous manner with a constant knee extension frequency (15 con-
tractions per min) and resistance (7+0% of MVC; range 2.0–6.0 kg) while
the left leg was at rest.22 Muscle perfusion and oxygen uptake were
measured in quadriceps femoris muscle (Figure 1), as described earlier,
during the first and second exercise bouts.22 The positron-emitting
tracers were produced in a standardized manner23 and an ECAT
931/08 tomograph (Siemens/CTI, Knoxville, TN, USA) was used for
emission scanning. All PET data were collected and analysed, as
previously shown.24,25
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Skeletal muscle and adipose tissue biopsies
Skeletal muscle biopsies from the vastus lateralis muscle were taken
using Bergstrom needles under local lidocaine anaesthesia. The biopsy
sample was immediately frozen in liquid nitrogen. Surgical biopsies
from subcutaneous adipose tissue were taken under local lidocaine
anaesthesia from midway between the iliac crest and the umbilicus.
The biopsy was immediately frozen in liquid nitrogen for further analysis.
mtDNA quantification
Genomic DNA was extracted from adipose tissue and skeletal muscle with
the QIAamp DNA isolation kit (Qiagen, Hilden, Germany). mtDNA and
nuclear DNA (nDNA) copy numbers were determined by quantitative PCR
using the ABI 7700 sequence detection system (Applied Biosystems,
Foster City, CA, USA). We amplified the mtDNA ATP-6 gene between nucleo-
tide positions 8981 and 9061 with the forward primer 5′-ACCAATAGCCCTGGC
CGTAC-3′ and the backward primer 5′-GGTGGCGCTTCCAATTAGGT-3′.
mtDNA was quantified with a FAM-fluorophore-labelled probe (5′-6FAM-
CCTAACCGCTAACATTACTGCAGGCCACC-TAMRA-3′). For the detection of
nDNA, we selected exon 8 of the GAPDH gene between nucleotide pos-
itions 4280 and 4342, using the forward primer 5′-CGGGGCTCTCCAGA
ACATC-3′ and the backward primer 5′-ATGACCTTGCCCACAGCCT-3′. In
this case, we used a VIC-fluorophore-labelled probe (5′-VIC-CCCTGCCT
CTACTGGCGCTGCC-TAMRA-3′).
Each 25 mL reaction contained 25 ng of genomic DNA, 100 nM of
probe, 200 nM of primers and Taq-man Universal Master Mix (Applied Bio-
systems, Foster City, CA, USA). Amplifications of mitochondrial and
nuclear products were separately performed in optical 96-well plates
(Applied Biosystems, Foster City, CA, USA). An initial incubation at 508C
for 2 min was followed by 10 min at 958C and 40 denaturing steps at
958C (15 s), alternating with combined annealing/extension at 608C
(1 min). All samples were run in triplicate. Absolute mtDNA and nDNA
copy numbers were calculated using serial dilutions of plasmids with
known copy numbers.
Laboratory parameters
Serum free insulin was determined by time-resolved fluoroimmunoassay
using an Insulin Kit (AUTOdelfia, Wallac, Turku, Finland). Plasma glucose
concentrations were measured by a hexokinase method using an auto-
analyser (Roche Diagnostics Hitachi 917, Hitachi Ltd, Tokyo, Japan). The
homeostasis model assessment of insulin resistance (HOMA) was
calculated from the formula: fasting glucose (mmol/L)×fasting insulin
(mU/L)/22.5.26 Serum total and high-density lipoprotein (HDL) cholesterol
as well as triglyceride concentrations were determined with respective
enzymatic kits from Roche Diagnostics using the Roche Diagnostics
Hitachi 917 autoanalyser. Plasma lactate concentrations were measured
using an enzymatic colorimetric method (Cobas Integra 400, Roche Diag-
nostics GmbH, Mannheim, Germany). The CD4+ cell count was deter-
mined using a flow cytometric apparatus (FACSort/FACSCalibur, Becton
Dickinson, San Jose´, CA, USA). The HIV viral load was measured using
the HPS Cobas TaqMan 48n HIV-1 Test (Roche Diagnostics, Branchburg,
NJ, USA), with a detection limit of 1.7 log10 copies/mL.
Statistical analysis
The unpaired t-test was used for comparison of differences between
the study groups after logarithmic transformation when necessary. Cor-
relations were calculated using Spearman’s rank correlation coefficient.
All data are given as means+SEM.
Results
Physical and biochemical characteristics (Table 1)
All participants (n¼10) were male and the groups were compar-
able with respect to age, body weight and body mass index.
Oxygen consumption
Perfusion
Resting leg Exercising leg
Figure 1. Examples of parametric perfusion and oxygen uptake PET
images during dynamic knee-extension exercise. The red colour
corresponds to high perfusion and oxygen uptake, and the dark colour
corresponds to low perfusion and oxygen uptake. The figure illustrates
significantly increased perfusion and oxygen uptake in the right
exercising quadriceps femoris muscle during the knee-extension
exercise, which specifically activates this muscle, whereas the levels of
perfusion and oxygen uptake remain low in the resting left leg. This
figure appears in colour in the online version of JAC and in black and
white in the print version of JAC.
Table 1. Characteristics of the study groups: HIV-infected, antiretroviral-
treated patients with LA (LA+) and without LA (non-LA)
Variable LA+ (n¼5) Non-LA (n¼5) P value
Age (years) 51+5 47+6 0.7
Body weight (kg) 69.1+5.0 78.6+3.8 0.2
Body mass index (kg/m2) 22.4+1.5 24.5+1.0 0.3
Total limb fat (g) 1120+450 5740+740 0.0008
Intra-abdominal fat (cm3) 2220+360 960+140 0.012
Leg lean mass (g) 18940+1220 19160+1440 0.9
Plasma glucose (mmol/L) 8.1+2.2 5.2+0.2 0.2
Serum insulin (mU/L) 13.0+2.3 4.6+0.7 0.008
HOMA 4.1+0.9 1.1+0.2 0.01
Serum triglycerides (mmol/L) 3.5+0.3 1.7+0.4 0.008
Serum cholesterol (mmol/L) 5.2+0.7 4.9+0.4 0.7
Serum LDL cholesterol (mmol/L) 2.1+0.5 2.5+0.5 0.6
Serum HDL cholesterol (mmol/L) 1.1+0.1 1.7+0.1 0.02
Haemoglobin (g/L) 133+6 147+7 0.2
MVC (N) 49+5 56+9 0.5
HOMA, homeostasis model assessment of insulin resistance [fasting glucose
(mmol/L)×fasting insulin (mU/L)/22.5]; LDL, low-density lipoprotein;
HDL, high-density lipoprotein; MVC, maximal isometric knee-extension
contraction force; N, newton.
Data are means+SEM.
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The patients in the non-LA group had 5-fold more limb fat than
the LA+ group. Conversely, the LA+ group had twice as much
intra-abdominal fat as the non-LA group. The lean mass of the
legs was almost identical between the groups.
Patients in the LA+ group had significantly higher serum
insulin concentrations and HOMA indices than the non-LA
group. The LA+ group also had other biochemical features of
insulin resistance, including increased serum triglyceride and
decreased serum HDL cholesterol concentrations. Blood haemo-
globin concentrations were similar between the groups.
HIV-related characteristics
The time since diagnosis of the HIV infection was
12.3+2.6 years in the LA+ group versus 6.2+1.8 years
(P¼0.09) in the non-LA group. The duration of combination
ART with at least three different drugs was longer in the
LA+ group than in the non-LA group (6.2+0.6 versus
2.9+0.5 years; P¼0.003). The cumulative exposure to thymidine
analogues (including also monotherapy prior to the era of
combination therapy) was longer in the LA+ group than in the
non-LA group (8.8+1.3 versus 2.7+0.6 years; P¼0.003). The
most recent viral load was below the detection limit in 9 out
of 10 study participants. One patient had a viral load of
252 copies/mL; his metabolic profile was not different when
compared with the other study subjects. The most recent CD4
count was almost identical between the groups (480+121
versus 488+63×106/L in the LA+ versus the non-LA group;
P¼0.96).
Two patients in the LA+ group were receiving zidovudine and
three were taking stavudine. In the non-LA group, four patients
were taking zidovudine and one patient did not take any
thymidine-analogue NRTI. The single patient not receiving a
thymidine-analogue NRTI at the time of the study had previously
been treated with zidovudine and stavudine. He did not show a
different metabolic pattern from the rest of the non-LA group.
Four patients in the LA+ group and one patient in the non-LA
group were receiving a protease inhibitor, and one versus four
patients were taking a non-nucleoside reverse transcriptase
inhibitor, respectively.
mtDNA quantification (Figure 2)
The mtDNA content in subcutaneous adipose tissue in the
LA+ group was approximately half of that in the non-LA group,
whereas the mtDNA content in skeletal muscle was almost
identical between the two study groups.
Skeletal muscle perfusion and oxygen consumption
The MVC was similar between the groups (Table 1).
Perfusion in resting (P¼0.5) and exercising (P¼0.9) quadri-
ceps femoris muscle were similar between the study groups
(Figure 3a). Similarly, the mean absolute (277+30 versus
274+43 mL/kg/min in the LA+ versus non-LA group; P¼0.95)
and relative (10.6+2.5- versus 11.9+1.5-fold change, respect-
ively; P¼0.67) increases in perfusion over resting values in
response to exercise were similar between the groups.
Oxygen consumption in skeletal muscle at rest was identical
(P¼0.9) between the groups (Figure 3b). During exercise,
oxygen consumption (P¼0.3) was also comparable between
the groups, although the interindividual variation was greater
than at rest. The mean absolute (14.6+1.7 versus
24.3+8.8 mL/kg/min in the LA+ versus non-LA group; P¼0.3)
and relative (10.3+2.8- versus 11.7+2.4-fold change, respect-
ively; P¼0.73) exercise-induced increases in oxygen consump-
tion were not significantly different between the groups
(Figure 3b). Likewise, there were no significant differences in
the oxygen extraction fraction between the groups at rest
(P¼0.7) or during exercise (P¼0.3) (Figure 3c).
Plasma lactate concentrations
Plasma lactate levels were higher in the LA+ versus the non-LA
group at rest before both periods of exercise (period 1,
1.8+0.2 versus 1.0+0.2 mmol/L; P¼0.02 and period 2,
1.9+0.2 versus 1.1+0.2 mmol/L; P¼0.03). Plasma lactate con-
centrations remained similarly higher in the LA+ versus the
non-LA group at the end of exercise during both periods
(period 1, 1.8+0.2 versus 1.2+0.1 mmol/L; P¼0.03 and period
2, 1.8+0.2 versus 1.0+0.1 mmol/L; P¼0.01). There was no sig-
nificant change in lactate concentration from baseline (at rest)
through to the end of the exercise period in either group.
Correlations among all study participants
The mtDNA content in subcutaneous adipose tissue correlated
with the amount of limb fat (r¼0.70, P¼0.04), whereas the
amount of mtDNA in skeletal muscle did not correlate with the
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Figure 2. Amount of mtDNA per nucleus in subcutaneous adipose tissue (a) and skeletal muscle (b) in HIV-infected, antiretroviral-treated patients
with LA (black bars) and without LA (white bars). Error bars indicate SEM.
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amount of leg lean mass (r¼0.3, P¼0.5). The HOMA index
tended to correlate inversely with the mtDNA content in subcu-
taneous adipose tissue (r¼20.59, P¼0.08), but not with the
mtDNA content in skeletal muscle (r¼20.37, P¼0.3). The
HOMA index also tended to correlate inversely with limb fat
mass (r¼20.65, P¼0.07).
MVC tended to correlate with the amount of skeletal muscle
mtDNA (r¼0.60, P¼0.07). Both MVC and mtDNA in skeletal
muscle correlated positively with perfusion (r¼0.68, P¼0.03
and r¼0.71, P¼0.03, respectively) and with oxygen consump-
tion (r¼0.72, P¼0.02 and r¼0.77, P¼0.01, respectively) during
exercise (Figure 4). There were no significant correlations
between mtDNA in skeletal muscle or MVC with perfusion rate
or oxygen consumption at rest.
The cumulative exposure to thymidine-analogue NRTI therapy
correlated inversely with the amount of subcutaneous fat (limb
fat r¼20.78, P¼0.03) and positively with insulin resistance
(HOMA r¼0.72, P¼0.03), but not with skeletal muscle perfusion
or oxygen consumption at rest or during exercise.
Discussion
In the present study, the amount of mtDNA in skeletal muscle
was not decreased in HIV-infected, antiretroviral-treated patients
with LA when compared with HIV-infected, antiretroviral-treated
patients without LA. Furthermore, oxygen consumption
measured by PET scanning in skeletal muscle during standardized
exercise was similar between these two study groups. These
data imply that drug-induced mitochondrial toxicity causing
LA does not affect all human tissues in a similar fashion
and that skeletal muscle remains spared in patients with
ART-associated LA.
The mtDNA content in skeletal muscle was not different
between the LA+ and the non-LA groups, although the
LA+ group had lower mtDNA content in the subcutaneous
adipose tissue. The observation of low mtDNA content in lipo-
atrophic adipose tissue is in agreement with previous data from
different groups.5,6 The content of mtDNA in skeletal muscle in
the context of lipodystrophy has been reported in a few previous
studies. Our finding is consistent with the study by Haugaard
et al.,27 who found similar mtDNA content in skeletal muscle
between lipodystrophic and non-lipodystrophic HIV-infected
patients. In the same study, there was no difference in skeletal
muscle mtDNA content in patients taking versus not taking stavu-
dine,27 which is the drug most strongly associated with a loss of
mtDNA content in subcutaneous fat. In contrast, Vittecoq
et al.28 reported low mtDNA copy numbers in skeletal muscle in
lipodystrophic patients when compared with healthy controls. In
their study, the inclusion criterion for the lipodystrophic group
was the presence of at least two severe adverse effects. Twenty
out of 21 patients in this study also had either neuropathy or
amyotrophia and, hence, the observed abnormalities may be
linked with these other complications of therapy rather than lipo-
dystrophy.28 In addition to these studies, Zaera et al.29 measured
mitochondrial protein content per milligram of skeletal muscle.
Mitochondrial protein contents did not differ between
HIV-infected lipodystrophic, HIV-infected non-lipodystrophic and
healthy control subjects.29
Mitochondrial RNA (mtRNA) has been found to be decreased
in adipose tissue of HIV-negative subjects after 2 weeks of
exposure to NRTIs, even in the absence of depletion of
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Figure 3. Perfusion (a), oxygen consumption (b) and oxygen extraction
fraction (c) at rest and during exercise in quadriceps femoris muscle of
HIV-infected, antiretroviral-treated patients with LA (black bars) and
without LA (white bars). Error bars indicate SEM.
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Figure 4. Relationship between the amount of mtDNA in skeletal muscle
and oxygen consumption (r¼0.77, P¼0.01) during exercise in quadriceps
femoris muscle of HIV-infected, antiretroviral-treated patients with LA
(filled circles) and without LA (open circles).
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mtDNA.30 The transcription of mtRNA has not been studied
in skeletal muscle of HIV-infected patients and it was not
evaluated in the present study.
Some aspects of mitochondrial function in skeletal muscle
have been evaluated by different ex vivo methods in HIV-infected
patients. The enzyme activity of mitochondrial respiratory
complex I has been reported to be unchanged29,31 or
decreased28 in skeletal muscle of lipodystrophic patients as com-
pared with controls. The activity of complex II has been reported
to be unchanged in two studies,29,31 whereas the activities of
complexes III and IV have been reported to be lower than in
control subjects.28,29,31 The activity of citrate synthase (a citric
acid cycle enzyme) and hydroxyacyl-coenzyme A dehydrogenase
(a mitochondrial enzyme catalysing the oxidation of fatty acids
to acetyl-coenzyme A) were not different at rest or during exer-
cise between lipodystrophic (or hyperlactataemic) HIV-infected
patients versus healthy controls.32 Also, the muscle glycogen
content and the concentrations of IMP, AMP, ADP and ATP were
similar between the groups.32 It is, however, difficult to evaluate
how much lipodystrophy per se contributed to the reported
findings due to the heterogeneity of the study populations, e.g.
in some studies the lipodystrophic patients had to present with
additional complications and the control groups varied from
healthy controls to HIV-infected treatment-naive patients with
uncontrolled viral replication.28,29,31,32 HIV infection per se may
play an important confounding effect, as was demonstrated
in a study showing increased apoptosis in skeletal muscle in
patients with HIV compared with non-infected persons;
however, among the HIV-infected patients the apoptosis rate
was similar in those with and without lipodystrophy.33
Recently, significant differences in mitochondrial function
have been described in skeletal muscle in different anatomical
sites. When HIV-negative patients with type 2 diabetes were
compared with healthy controls, reduced mitochondrial function
in diabetic patients was only present in the lower and not
the upper limb skeletal muscle.34 No study has yet evaluated
mitochondrial function in the upper limb skeletal muscle in
HIV-infected patients.
We evaluated whether skeletal muscle aerobic metabolism,
which is partly dependent on myocellular mitochondrial
function but also on oxygen delivery (perfusion), is affected in
HIV-infected, antiretroviral-treated patients with lipodystrophy
compared with HIV-infected, antiretroviral-treated patients
without lipodystrophy. The PET technique used in the study allows
direct in vivo measurement of muscle perfusion and oxygen con-
sumption.19 To our knowledge, this is the first study using PET scan-
ning for the determination of the integrity of skeletal muscle
exercise capacity in the context of ART-associated lipodystrophy.
Oxygen consumption was similar between the LA+ and
non-LA groups, both at rest and during standardized exercise.
In addition, muscle perfusion, which affects muscle oxygen
supply, and oxygen extraction were similar between the study
groups. The exercise intensity (7% of maximal force) was kept
low enough in order not to exceed the aerobic capacity. The
low concentration of blood lactate in both groups during exercise
is consistent with the aerobic exercise intensity. The ability of the
LA+ group to perform the same workload by consuming the
same amount of oxygen without any increase in blood lactate
as the non-LA group implies similar mitochondrial respiratory
chain function, i.e. ATP production.
A recent DEXA modelling study suggests that increased resting
energy expenditure in patients with LA could be explained by a
hypermetabolic state in skeletal muscle.35 However, the direct
measurements of blood perfusion and oxygen consumption in
skeletal muscle in the current study do not support this model.
In the present study, the blood oxygen carrying capacity, as
determined from the haemoglobin concentration, was similar
between the groups. Mitochondrial efficiency to produce ATP is
also dependent on physical fitness. In the current study, the
maximal voluntary isometric contraction force of knee extensors,
which indirectly indicates physical fitness, was similar between
the groups, and the leg lean tissue mass was also almost iden-
tical between the groups.
Previous studies evaluating the skeletal muscle performance
in patients with ART-associated lipodystrophy have used incre-
mental exercise tests until exhaustion. Our findings are in line
with those by Roge et al.,32 who found no evidence of significant
damage to skeletal muscle mitochondrial function in lipo-
dystrophic patients compared with healthy controls. In this
study, the lipodystrophic patients had higher blood lactate con-
centrations at rest, but there was no significant difference in
the maximal lactate levels or in the decline in blood lactate
during the recovery period.32 In contrast, in the study by
Chapplain et al.,31 lipoatrophic patients reached the lactic acido-
sis threshold at a lower workload and had lower maximum
power output than antiretroviral-treated non-lipodystrophic
patients; findings were considered to be due to mitochondrial
dysfunction. However, these results may be confounded by the
fact that the lipodystrophic patients were less fit than the non-
lipodystrophic subjects.31
Further indirect evidence for the lack of substantial and at
least irreversible mitochondrial toxicity in skeletal muscle in
patients with ART-associated lipodystrophy comes from physical
training interventions. In a randomized study with lipodystrophic
patients, the peak oxygen uptake increased significantly in the
exercise and diet group, whereas there was no change in the
diet-only group.36 Other studies have similarly shown improve-
ment in exercise tolerance and aerobic fitness in patients with
ART-associated lipodystrophy after training programmes during
ongoing ART.37,38 Furthermore, both endurance and strength
training have improved skeletal muscle glucose uptake
measured by clamp studies in patients with ART-associated lipo-
dystrophy.39 These data demonstrating an improvement in skel-
etal muscle function contrast the data from adipose tissue,
where several studies have shown continuous worsening of LA
during ongoing thymidine analogue NRTI (tNRTI)-containing
ART.40 – 42 In contrast, significant improvement in LA has been
shown in clinical trials after switching away from a thymidine
analogue.43 This clinical improvement has been associated
with a statistically significant increase in mtDNA content in
adipose tissue, but not in skeletal muscle.44 This again implies
a different response in adipose tissue versus skeletal muscle.
During recent years, genetic studies have been performed
to evaluate susceptibility to LA and/or mitochondrial damage
during ART. Haemochromatosis gene polymorphism (HFE
187CG) and mitochondrial haplotype J have been associated
with a reduced risk of developing LA.45 No genetic studies were
performed in the present study.
The limitations of the current study include its small size due
to complex methodology. Furthermore, the results do not
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exclude the possibility that some antiretroviral agents may cause
damage in skeletal muscle under certain circumstances, e.g. 1
month exposure to stavudine as compared with placebo in
healthy volunteers decreased the mtDNA content in skeletal
muscle and insulin sensitivity, as measured by hyperinsulinaemic
euglycaemic clamp, without changes in body composition.46 Our
study focused on the potential inter-relations between LA and
skeletal muscle, and we did not include a healthy unexposed
control group. Therefore, we cannot exclude the possibility that
there were some identical changes in skeletal muscle in both
the LA+ and non-LA groups as compared with healthy subjects.
Our results, however, clearly imply that those pathophysiological
changes leading to LA in adipose tissue do not occur in a similar
fashion and extent in skeletal muscle. Since none of the patients
had any clinical signs of myopathy, these results cannot be gen-
eralized to patients with the well-characterized condition of
zidovudine-associated myopathy. Intermuscular adipose tissue,
the role of which is under investigation in HIV-related metabolic
abnormalities,47 was not evaluated in the present study.
In conclusion, data from the current study imply that
although HIV-infected patients with ART-associated LA have
decreased mtDNA content in subcutaneous fat, they have
similar mtDNA content in skeletal muscle and comparable skel-
etal muscle aerobic exercise metabolism as HIV-infected,
antiretroviral-treated non-LA patients. NRTIs seem to cause
mitochondrial defects in adipose tissue, but to spare skeletal
muscle function in these patients. The tissue specificity of mito-
chondrial toxicity in ART-associated LA is reminiscent of other
mitochondrial diseases, which in general demonstrate tissue
specificity.48,49
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